Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term doxorubicin. Found 31 abstracts

no pagination
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.   PMCID: PMC5531172
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract I. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug;121(15):2586-93.
Cook JR, Goldman B, Tubbs RR, Rimsza L, Leblanc M, Stiff P, Fisher R. Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas A SWOG S9704 Correlative Study. American Journal of Surgical Pathology. 2014 Apr;38(4):494-501.   PMCID: PMC 3955880
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 2012 Apr;18(7):2056-65.
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A Phase 2 Trial of Bortezomib Followed by the Addition of Doxorubicin at Progression in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck A Trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011 Aug;117(15):3374-82.   PMCID: PMC3135694
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2010 May;117(2):324-9.   PMCID: NIH funded - needs PMCID
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansar R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(13):2038-43.
Ozols RF, Bookman MA, Young RC, Du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. GYNECOLOGIC ONCOLOGY. 2006 Oct;103(1):1-6.
Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium - A trial of the eastern cooperative oncology group. Cancer. 2004 Apr;100(8):1639-45.
Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical Cancer Research. 2004 Nov;10(21):7220-8.
Gervasoni JE, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer research. 2004 Sep;24(5A):2617-26.
Garcia AA, Bookman MA, Rodriguez-Rodriguez L, Mutch DG, Look KY. Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies - A Gynecologic Oncology Group study. Investigational New Drugs. 2002 Nov;20(4):383-7.
Ozols RF. Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin. Cancer Journal from Scientific American. 1999 Nov;5(6):336-8.
Pulfer SK, Ciccotto SL, Gallo JM. Distribution of small magnetic particles in brain tumor-bearing rats. Journal of Neuro-Oncology. 1999 Jan;41(2):99-105.
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P. 5-fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer - An Eastern Cooperative Oncology Group phase II study (E1889). American Journal of Clinical Oncology-Cancer Clinical Trials. 1998 Apr;21(2):171-6.
Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Seminars in Oncology. 1998 Jun;25(3):326-34.
Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. Journal of Drug Targeting. 1998 Jan;6(3):215-27.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term doxorubicin

doxorubicin chemotherapy cisplatin cyclophosphamide paclitaxel carcinoma cancer trial vincristine therapeutic use combination permeability Male Oncology stage-iii prednisone Adult gynecologic-oncology-group Doxorubicin combination chemotherapy Antineoplastic Combined Chemotherapy Protocols magnetic field disease gemcitabine administration & dosage mortality Female targeted drug delivery albumin microspheres 80 and over Aged methotrexate surface platinum-resistant Aged drug therapy Middle Aged vinblastine survival phase-ii unclassifiable with features intermediate between DLBCL and BL COMBINATION glioma models cells in-vivo MYC integrity plus cisplatin chemotherapeutic-agents necrosis Disease control mitomycin-c tissue distribution particle size analogs & derivatives mutations phase-iii randomized trial liposomal Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor modulator quality of life rituximab plus cyclophosphamide Neoadjuvant Therapy ii trial microspheres and prednisone (R-CHOP) KeyWords Plus: salivary-gland carcinomas apoptosis sdz psc 833 sgn-30 multidrug-resistance stem-cell transplantation randomized-trial alpha(5)beta(1) integrin kappa-b-alpha remission pegylated liposomal paclitaxel-resistant family Progression-free muscle invasion 2nd- epithelial ovarian-cancer early stage braf mutations Platinum resistant 5-fluorouracil topotecan classification bcl2 carboplatin oncology-group hematologic malignancies platinum Volociximab dexamethasone Chemoradiotherapy SURVIVAL braf(v600e) mutation single-agent carboplatin barrier transport adriamycin Ovarian cancer colorectal-carcinoma vegf head and neck cancer Cisplatin stage-iii ovarian intergroup trial criteria prostate cancer aminodextran Transitional Cell Carcinoma response phase-ii trial kinase kinase-1 pathology 1st-line treatment circulating tumor-cells nonsmall cell lung platinum-refractory ovarian hexamethylmelamine consolidation proteasome inhibitor ps-341 rats bladder cancer alpha 5 beta 1 integrin abnormalities ptc features 2 inhibitor growth-factor resistance Follow-Up Studies Muscle Neoplasms REGIMEN cell-lung-cancer gemcitabine plus cisplatin therapy angiogenesis Prospective Studies look laparotomy transport Treatment Outcome ferrofluid immunohistochemistry Prednisone modulation peritoneal carcinoma
Last updated on Wednesday, August 12, 2020